Liminal BioSciences Inc. PFSCF

RE:RE:RE:Bought Deal

[hiya1969]

Why are you guys surprised ? what has PLI done to hide things ? What conspiracy ?.....Fred told us all about this in late April when i emailed him, nothing was hidden, held back, lied about................let the company manage, if you dont like it, sell..............try at least to have some faith, just a little, ...........oh,  and some patience too..............here is the email answer from Fred.....

That is a very good question XXXXX and one that I am afraid I can’t answer with certainty or a fair degree of precision. We only control what is related to the execution of our clinical programs and operations. On that front, we are moving forward full steam ahead with our plans. If we execute as I thing we will, it’s only a question of time before the share price starts to move again.

We will have to do a few things in the meantime, such as alleviate concerns related to financings. Fixing the balance sheet will obviously help as investors get nervous when there is less than 1 year of cash ahead. Getting our first product approved by the FDA will also help tremendously as it will de-risk the platform and demonstrate that we can take a protein from plasma and bring it all the way to market. This should take place later in 2017. In the meantime, we continue to work on potential partnerships and hope to be able to close some during this year.

If we execute as planned, the share price will have no choice but to adjust accordingly in my opinion.

Hope this helps and I hope to see you at the AGM in May

Best regards,

Fred

Frederic Dumais
Directeur principal, Communications et relations avec les investisseurs, Senior Director, Communications and Investor Relations
image001.png
440 Boul. Armand-Frappier
Laval, Quebec H7V 4B4
image002.png [phone]
image003.png [e-mail]
Avis : Ce courriel est confidentiel et est l'usage exclusif du destinataire. Si vous n’tes pas le ou la destinataire vis(e), veuillez nous en informer immdiatement par courriel, effacer l'original sans en conserver de copie et ne pas en dvoiler le contenu ni utiliser l’information pour quelque fin que ce soit.
Notice : This e-mail is confidential and intended for the exclusive use of the addressee. If you are not the intended addressee, please notify us immediately by e-mail, delete the original without keeping a copy and do not disclose its content or use the information for any purposes.